The leading Integrated Research Organization Javara recently announced a new strategic partnership with Cape Fear Valley Health. Leveraging Javara’s integrated teams and infrastructure, Cape Fear Valley Health will now offer clinical trial opportunities to their diverse patient population in Fayetteville, North Carolina and the surrounding areas.

A multi-specialty health system with eight hospitals, an emerging medical school in partnership with Methodist University and over 1,000 physicians, Cape Fear Valley Health currently serves eight counties in the southeastern portion of the state. Javara will employ and embed experienced clinical research staff within Cape Fear Valley Health clinics to work alongside their physicians and medical teams to scale trial operations and provide personalized care for patients electing to participate in clinical research.

“Cape Fear Valley’s presence across North Carolina is vast. Their facilities and patient reach offer an unparalleled opportunity to improve population health through access to clinical trial participation,” said Javara Founder and CEO Jennifer Byrne in a press release. “Through this partnership, we are driving forward a more inclusive clinical trial landscape — delivering access where it's needed most in the greater Fayetteville area and strengthening research efforts in oncology and beyond.”

With prior research experience, Cape Fear Valley Health is perfectly positioned to maximize the impact of an integrated approach to trial delivery. Specialty and Therapeutic Capabilities will include Oncology, Cardiology, Neurology, Psychiatry, Pediatrics, Women’s Health and Family Health.

“This collaboration with Javara restores a critical pathway for patients in our community to access clinical trials,” said Cape Fear Valley Health Chief Medical Officer Samual Fleishman, MD, in a press release. “Cape Fear Valley and Javara share a common goal to improve access to healthcare in underserved populations through clinical trials. This partnership enables us to again bring new interventions and cutting-edge treatments to our patients.”